Wedbush initiated coverage of Zenas Biopharma with a rating of Outperform and set a new price target of $35.00

Wolfe Research initiated coverage of Zenas Biopharma with a rating of Outperform and set a new price target of $19.00

H.C. Wainwright initiated coverage of Zenas Biopharma with a rating of Buy and set a new price target of $30.00

Rodman & Renshaw initiated coverage of Zenas Biopharma with a rating of Buy and set a new price target of $34.00

Guggenheim initiated coverage of Zenas Biopharma with a rating of Buy and set a new price target of $45.00

Morgan Stanley initiated coverage of Zenas Biopharma with a rating of Overweight and set a new price target of $40.00

Jefferies initiated coverage of Zenas Biopharma with a rating of Buy and set a new price target of $35.00

Citigroup initiated coverage of Zenas Biopharma with a rating of Buy and set a new price target of $27.00

SCHEDULE 13G/A - Zenas BioPharma, Inc. (0001953926) (Subject)

8-K - Zenas BioPharma, Inc. (0001953926) (Filer)

S-8 - Zenas BioPharma, Inc. (0001953926) (Filer)

10-Q - Zenas BioPharma, Inc. (0001953926) (Filer)

8-K - Zenas BioPharma, Inc. (0001953926) (Filer)

SCHEDULE 13G/A - Zenas BioPharma, Inc. (0001953926) (Subject)

8-K - Zenas BioPharma, Inc. (0001953926) (Filer)

SCHEDULE 13D - Zenas BioPharma, Inc. (0001953926) (Subject)

8-K - Zenas BioPharma, Inc. (0001953926) (Filer)

10-Q - Zenas BioPharma, Inc. (0001953926) (Filer)

4 - Zenas BioPharma, Inc. (0001953926) (Issuer)

4 - Zenas BioPharma, Inc. (0001953926) (Issuer)

4 - Zenas BioPharma, Inc. (0001953926) (Issuer)

4 - Zenas BioPharma, Inc. (0001953926) (Issuer)

4 - Zenas BioPharma, Inc. (0001953926) (Issuer)

4 - Zenas BioPharma, Inc. (0001953926) (Issuer)

4 - Zenas BioPharma, Inc. (0001953926) (Issuer)

4 - Zenas BioPharma, Inc. (0001953926) (Issuer)

4 - Zenas BioPharma, Inc. (0001953926) (Issuer)

4 - Zenas BioPharma, Inc. (0001953926) (Issuer)

Initial $75 million to fund the potential U.S. commercial launch of obexelimab for the treatment of IgG4-Related DiseaseAdditional $150 million associated with the upcoming results of the obexelimab Phase 3 INDIGO trial and FDA approval for the treatment of IgG4-Related Disease NEW YORK and WALTHAM, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) and Zenas BioPharma, Inc. (NASDAQ:ZBIO) today announced that Royalty Pharma will provide up to $300 million in funding in exchange for a royalty on sales of obexelimab. "We are delighted to partner with Zenas as they develop obexelimab in IgG4-RD and other autoimmune diseases," said Pablo Legorreta, founder and CEO

- Initial $75 million to fund the potential U.S. commercial launch of obexelimab for the treatment of IgG4-Related Disease - - Additional $150 million associated with the upcoming results of the obexelimab Phase 3 INDIGO trial and FDA approval for the treatment of IgG4-Related Disease - WALTHAM, Mass. and New York, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (NASDAQ:ZBIO), and Royalty Pharma plc (NASDAQ:RPRX) today announced that Royalty Pharma will provide up to $300 million in funding in exchange for a royalty on sales of obexelimab. "We are very pleased to partner with Royalty Pharma as we rapidly advance our broad obexelimab program through late-stage development

WALTHAM, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. ("Zenas" or the "Company") (NASDAQ:ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for autoimmune diseases, today announced management's presentations at the following investor conferences in September: Citi's 2025 Biopharma Back to School Conference on Tuesday, September 2, 2025, at 1:00 p.m. ETCantor Global Healthcare Conference 2025 on Wednesday, September 3, 2025, at 8:35 a.m. ETMorgan Stanley 23rd Annual Global Healthcare Conference on Wednesday, September 10, 2025, at 7:45 a.m. ET Live webcasts and archived

- Topline results from pivotal Phase 3 INDIGO trial in Immunoglobulin G4-Related Disease expected around year-end 2025 - - Completed enrollment of Phase 2 MoonStone trial in Relapsing Multiple Sclerosis; results expected early in the fourth quarter 2025 - - Enrollment of Phase 2 SunStone trial in Systemic Lupus Erythematosus expected to be completed by year-end 2025; topline results expected mid-2026 - - Cash, cash equivalents and investments of $274.9 million as of June 30, 2025, expected to provide cash runway into the fourth quarter of 2026 - WALTHAM, Mass., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. ("Zenas" or the "Company") (NASDAQ:ZBIO), a clinical-s

WALTHAM, Mass., June 20, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. ("Zenas" or the "Company") (NASDAQ:ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of therapies for autoimmune diseases, today announced that on June 16, 2025 (the "Grant Date"), the Compensation Committee of the Company's Board of Directors granted a non-qualified stock option to purchase 112,000 shares of the Company's common stock to a newly hired employee of the Company as an inducement material to such employee's entry into employment with the Company, in accordance with Nasdaq Listing Rule 5635(c)(4) (the "Inducement Grant"). The Ind

WALTHAM, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. ("Zenas" or the "Company") (NASDAQ:ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of therapies for autoimmune diseases, today announced management's presentation at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025, at 1:25 p.m. ET. A live webcast and archived replay of the Company's presentation can be accessed under "Events and Presentations" in the Investor & Media Relations section of the Zenas BioPharma website. About Zenas BioPharma, Inc.Zenas is a clinical-stage global biopharmaceutical company committed to becomin

- Topline results from pivotal Phase 3 INDIGO trial in Immunoglobulin G4-Related Disease expected around year-end 2025 - - Phase 2 MoonStone trial in Relapsing Multiple Sclerosis enrollment concluding; topline results expected early in the fourth quarter 2025 - - Enrollment of Phase 2 SunStone trial in Systemic Lupus Erythematosus expected to be completed by year-end 2025; topline results expected mid-2026 - - Strengthened leadership team with appointments of Lisa von Moltke, M.D., Head of Research and Development and Chief Medical Officer, and Haley Laken, Ph.D., Chief Scientific Officer - - Cash, cash equivalents and investments of $314.2 million as of March 31, 2025, expected to provi

WALTHAM, Mass., April 17, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. ("Zenas" or the "Company") (NASDAQ:ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of therapies for autoimmune diseases, today announced that on April 15, 2025 (the "Grant Date"), the Compensation Committee of the Company's Board of Directors (the "Committee") granted non-qualified stock options to two newly hired officers of the Company, each as an inducement material to each officer's entry into employment with the Company, in accordance with Nasdaq Listing Rule 5635(c)(4). The Committee granted a non-qualified stock option to purchase

WALTHAM, Mass., April 07, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. ("Zenas" or the "Company") (NASDAQ:ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of therapies for autoimmune diseases, today announced the appointment of Haley Laken, Ph.D., as Chief Scientific Officer (CSO). Dr. Laken brings significant scientific insight and leadership experience in research, development operations, R&D strategy and business development. "Haley is an accomplished R&D leader with expertise in translational research, drug development and operations. She has advanced programs through the clinic leading to regulatory approv

–Dr. von Moltke brings over 30 years of deep drug development experience and a proven track record of clinical and regulatory success at both large and emerging global biopharmaceutical companies– WALTHAM, Mass., March 17, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. ("Zenas" or the "Company") (NASDAQ:ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of therapies for autoimmune diseases, today announced the appointment of Lisa von Moltke, M.D., as its Head of Research and Development and Chief Medical Officer (CMO). Dr. von Moltke brings over 30 years of U.S. and international drug development experience s

4/A - Zenas BioPharma, Inc. (0001953926) (Issuer)

4 - Zenas BioPharma, Inc. (0001953926) (Issuer)

4 - Zenas BioPharma, Inc. (0001953926) (Issuer)

4 - Zenas BioPharma, Inc. (0001953926) (Issuer)

4 - Zenas BioPharma, Inc. (0001953926) (Issuer)

4 - Zenas BioPharma, Inc. (0001953926) (Issuer)

4/A - Zenas BioPharma, Inc. (0001953926) (Issuer)

4 - Zenas BioPharma, Inc. (0001953926) (Issuer)

4 - Zenas BioPharma, Inc. (0001953926) (Issuer)

4 - Zenas BioPharma, Inc. (0001953926) (Issuer)

WALTHAM, Mass., April 07, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. ("Zenas" or the "Company") (NASDAQ:ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of therapies for autoimmune diseases, today announced the appointment of Haley Laken, Ph.D., as Chief Scientific Officer (CSO). Dr. Laken brings significant scientific insight and leadership experience in research, development operations, R&D strategy and business development. "Haley is an accomplished R&D leader with expertise in translational research, drug development and operations. She has advanced programs through the clinic leading to regulatory approv

–Dr. von Moltke brings over 30 years of deep drug development experience and a proven track record of clinical and regulatory success at both large and emerging global biopharmaceutical companies– WALTHAM, Mass., March 17, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. ("Zenas" or the "Company") (NASDAQ:ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of therapies for autoimmune diseases, today announced the appointment of Lisa von Moltke, M.D., as its Head of Research and Development and Chief Medical Officer (CMO). Dr. von Moltke brings over 30 years of U.S. and international drug development experience s

Initial $75 million to fund the potential U.S. commercial launch of obexelimab for the treatment of IgG4-Related DiseaseAdditional $150 million associated with the upcoming results of the obexelimab Phase 3 INDIGO trial and FDA approval for the treatment of IgG4-Related Disease NEW YORK and WALTHAM, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) and Zenas BioPharma, Inc. (NASDAQ:ZBIO) today announced that Royalty Pharma will provide up to $300 million in funding in exchange for a royalty on sales of obexelimab. "We are delighted to partner with Zenas as they develop obexelimab in IgG4-RD and other autoimmune diseases," said Pablo Legorreta, founder and CEO

- Initial $75 million to fund the potential U.S. commercial launch of obexelimab for the treatment of IgG4-Related Disease - - Additional $150 million associated with the upcoming results of the obexelimab Phase 3 INDIGO trial and FDA approval for the treatment of IgG4-Related Disease - WALTHAM, Mass. and New York, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (NASDAQ:ZBIO), and Royalty Pharma plc (NASDAQ:RPRX) today announced that Royalty Pharma will provide up to $300 million in funding in exchange for a royalty on sales of obexelimab. "We are very pleased to partner with Royalty Pharma as we rapidly advance our broad obexelimab program through late-stage development

SC 13G - Zenas BioPharma, Inc. (0001953926) (Subject)

SC 13G - Zenas BioPharma, Inc. (0001953926) (Subject)

SC 13G - Zenas BioPharma, Inc. (0001953926) (Subject)

SC 13D - Zenas BioPharma, Inc. (0001953926) (Subject)

SC 13D - Zenas BioPharma, Inc. (0001953926) (Subject)

SC 13D - Zenas BioPharma, Inc. (0001953926) (Subject)